Non-Small Cell Lung Cancer - Oncology Matrix

Durvalumab After Sequential Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer—Final Analysis From the Phase 2 PACIFIC-6 Trial

Research Summary: Unresectable, stage III non-small cell lung cancer (NSCLC) is treated with concurrent chemoradiotherapy (cCRT) followed by durvalumab for up to 12 months, which improves progression-free survival (PFS) and overall survival (OS) compared to cCRT alone. However, many patients receive sequential chemoradiotherapy (sCRT) rather...

ASCO Quality Care Symposium 2025: Non-Small Cell Lung Cancer

Guideline-concordant osimertinib and durvalumab in two US non-small cell lung cancer cohorts. In this study, researchers assessed rates of guideline-concordant care (GCC) with osimertinib and durvalumab among patients with nonmetastatic non-small cell lung cancer (NSCLC). Two cohorts from the Flatiron Health Research Database were analyzed....

Is Less More? A Meta-Analysis of Nonintubated Versus Intubated VATS for Anatomic Resections in Non-Small Cell Lung Cancer

Reprinted with permission. J Clin Med. 2025;14(19):6731.* by Dimitrios E. Magouliotis, Anna P. Karamolegkou, Prokopis-Andreas Zotos, Fabrizio Minervini, Ugo Cioffi, and Marco Scarci Dr. Magouliotis is with Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania. Dr. Karamolegkou is with Department of...

Journal Watch: Hot Topics in Non-small Cell Lung Cancer March 2026

SMARCA4 regulates SMARCAD1 expression for toleration of replication stress in non-small cell lung cancer Sawangsri P, Limsirichaikul S, Takeuchi T, et al. Fujita Med J. 2026;12(1):40–49. Summary. In SMARCA4-depleted non-small cell lung cancer (NSCLC) cells, SAMRCAD1 messenger ribonucleic acid and SMARCAD1 protein levels were upregulated....

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC

Research Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung cancer (NSCLC), and current first-line standards based on immune checkpoint inhibitors (ICIs), with or without chemotherapy, yield suboptimal long-term outcomes. Olomorasib is an orally bioavailable, highly selective KRAS G12C inhibitor...

Prognostic Impact of KRAS and SMARCA4 Mutations and Comutations on Survival in Non-Small Cell Lung Cancer: Insights from the AACR GENIE BPC Dataset

Reprinted with permission. Biomedicines. 2025;13(9):2142.* by Peter Manolakos, Yu-Bo Wang, Janice Withycombe, Luigi Boccuto, and Diana Ivankovic Dr. Manolakos is with Healthcare Genetics and Genomics PhD Program, Clemson University in Clemson, South Carolina. Dr. Bo-Wang is with School of Mathematical and Statistical Sciences, Clemson University...

European Society for Medical Oncology Congress 2025: Non-Small Cell Lung Cancer

Molecular characteristics and overall survival of STK11-mutant NSCLC according to KRAS mutation status. In this study, researchers compared clinical and molecular differences between STK11-mutant/KRAS-mutant non-small cell lung cancer (NSCLC) and STK11-mutant/KRAS-wildtype NSCLC. Data from 2022 to 2024 were included for analysis. Among 808 patients with...

Digital Editions